65,437 trials
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 9.6; 8.0; 7.3; 8.8 months — p=0.0234
Head and Neck Cancer
Primary: Overall Response Rate at 4 Months — 16 percentage of participants
Myopia
Primary: Percentage of Subjects With Same Fit in Both Eyes — 99.2; 100; 99.2; 99.2 percentage of participants
Adult Solid Tumor
Primary: Determine Maximum Tolerated Dose of TRC105 in Combination With Bevacizumab — 10 mg/kg
Hyperinsulinemia · Insulin Resistance · Obesity
Primary: Fasting Insulin — 8.1; 8.0; 6.3 uIU/mL — p=0.181
Gastroenteritis Rotavirus
Primary: Percentage of Participants With Any Adverse Experience — 22.12 Percent of participants
Sleep Apnea, Obstructive · Diabetes Mellitus, Type 2
Primary: Physical Activity, Steps Walked — 5892; 6071; 6284; 6684 steps walked
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-002358 — 43476 pg*h/ml
Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Three-dimensional Conformal Radiation Therapy (3DRT), in Terms of Gy Per Fraction, Combined With Concurrent Chemotherapy — 0; 1 units on…
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 21; 17; 1; 0 Subjects
Schizophrenia
Primary: Subjective Well-being Under Neuroleptic (SWN-20) Scale Total Score at Week 24 — 77.89 Units on a scale
Post-Operative Pain
Primary: Patient Global Satisfaction — 78.5; 65.6 % patients reporting good or excellent — p=<0.001
Human Papillomavirus (HPV) Infection
Primary: Percentage of Participants With Any Adverse Experience — 11.29 Percent of participants
Ankle Sprain
Primary: Pain on Movement — 31.3; 59.2 mm
Stroke · Carotid Stenosis
Primary: Transcranial Doppler Counts of Micro-embolic Signals in the Ipsilateral Middle Cerebral Artery. — 264; 339 Micro-emboli